OwlTail

Cover image of Julia Batten

Julia Batten

3 Podcast Episodes

Latest 9 Oct 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Julia Batten, APRN, MSN, MPH - Virginia J. Seery, MSN, RN, ANP-BC - The Urologic Nurse Meets the Challenge of Renal Cell Carcinoma: Insights on Patient Care in an Expanding Treatment Landscape

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/MDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView onDemand activity based on a nurse-led program at the SUNA 2019 uroLogic Conference, experts on modern RCC treatment (including immunotherapies and TKIs) offer valuable, practical insights on the current therapeutic and regulatory landscape in RCC, real-world application of evidence on novel targeted and immunotherapeutic regimens, the importance of counseling patients on therapeutic expectations with immune checkpoint inhibitors and TKIs, and the recognition and management of unique safety issues associated with newer agents in RCC. Upon completion of this activity, participants will be able to: Summarize the latest efficacy and safety findings on novel regimens, including immune checkpoint inhibitors, tyrosine kinase inhibitors, and combination approaches, for management of patients with renal cell carcinoma (RCC), Provide appropriate education and guidance to patients with RCC on available and emerging targeted- and immuno-therapeutic options in different disease settings, Counsel patients with RCC receiving immune checkpoint inhibitors and/or tyrosine kinase inhibitors on appropriate strategies to manage treatment-related complications

49mins

23 Oct 2019

Episode artwork

Julia Batten, APRN, MSN, MPH - Virginia J. Seery, MSN, RN, ANP-BC - The Urologic Nurse Meets the Challenge of Renal Cell Carcinoma: Insights on Patient Care in an Expanding Treatment Landscape

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/MDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView onDemand activity based on a nurse-led program at the SUNA 2019 uroLogic Conference, experts on modern RCC treatment (including immunotherapies and TKIs) offer valuable, practical insights on the current therapeutic and regulatory landscape in RCC, real-world application of evidence on novel targeted and immunotherapeutic regimens, the importance of counseling patients on therapeutic expectations with immune checkpoint inhibitors and TKIs, and the recognition and management of unique safety issues associated with newer agents in RCC. Upon completion of this activity, participants will be able to: Summarize the latest efficacy and safety findings on novel regimens, including immune checkpoint inhibitors, tyrosine kinase inhibitors, and combination approaches, for management of patients with renal cell carcinoma (RCC), Provide appropriate education and guidance to patients with RCC on available and emerging targeted- and immuno-therapeutic options in different disease settings, Counsel patients with RCC receiving immune checkpoint inhibitors and/or tyrosine kinase inhibitors on appropriate strategies to manage treatment-related complications

49mins

23 Oct 2019

Similar People

Episode artwork

Julia Batten, APRN, MSN, MPH - Virginia J. Seery, MSN, RN, ANP-BC - The Urologic Nurse Meets the Challenge of Renal Cell Carcinoma: Insights on Patient Care in an Expanding Treatment Landscape

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/MDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView onDemand activity based on a nurse-led program at the SUNA 2019 uroLogic Conference, experts on modern RCC treatment (including immunotherapies and TKIs) offer valuable, practical insights on the current therapeutic and regulatory landscape in RCC, real-world application of evidence on novel targeted and immunotherapeutic regimens, the importance of counseling patients on therapeutic expectations with immune checkpoint inhibitors and TKIs, and the recognition and management of unique safety issues associated with newer agents in RCC. Upon completion of this activity, participants will be able to: Summarize the latest efficacy and safety findings on novel regimens, including immune checkpoint inhibitors, tyrosine kinase inhibitors, and combination approaches, for management of patients with renal cell carcinoma (RCC), Provide appropriate education and guidance to patients with RCC on available and emerging targeted- and immuno-therapeutic options in different disease settings, Counsel patients with RCC receiving immune checkpoint inhibitors and/or tyrosine kinase inhibitors on appropriate strategies to manage treatment-related complications

49mins

23 Oct 2019